Shenzhen Yuanxing Gene-tech Co.,Ltd. ((www.yxgene.com), founded in 2015, is a national high-tech enterprise.The company has always focused on CDMO and CMO services for viral vectors (adenovirus, poxvirus, herpesvirus, lentivirus, adeno-associated virus, Newcastle disease virus, etc.), gene therapy drugs such as mRNA and new vaccines, which are widely used in gene therapy, viral vector vaccine, therapeutic vaccine, oncolytic virus project, gene editing and various cell therapies. The indications of the products under development cover various diseases such as new crown vaccine, rare diseases, tumors, virus infection, central nervous system diseases and so on. The company has a clean workshop of more than 7000 square meters meeting the GMP requirements, which can meet the pharmaceutical research of the whole process of viral vector and mRNA drugs, meet the application requirements of IND and BLA, and undertake the production of drug clinical trial samples and listed products. Since undertaking the development of viral vector gene therapy drugs and preclinical CMC services, it has carried out sample preparation and process research and development of nearly 100 viral vector projects, and accumulated rich experience in viral vector product research and development and CMC services. More than 10 projects have also obtained clinical approval and are currently undergoing clinical trials. At present, in the CDMO service field of undertaking viral vector gene therapy drugs in China, Yuanxing gene undertakes a wide variety of viruses, and the clinical approvals obtained are in the forefront. Yuanxing gene will continue to give full play to the advantages of gene therapy CDMO platform, continuously upgrade and optimize the platform process, and help the R & D and production of drugs such as gene therapy and cell therapy.